<DOC>
	<DOCNO>NCT00062049</DOCNO>
	<brief_summary>RATIONALE : Interleukin-7 may stimulate person 's white blood cell kill tumor cell . PURPOSE : This phase I trial study side effect best dose interleukin-7 treating patient refractory solid tumor .</brief_summary>
	<brief_title>Interleukin-7 Treating Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety dose-limiting toxicity biologically active dos interleukin-7 patient refractory solid tumor . - Determine range biologically active dos drug patient . - Determine biological effect drug patient . - Determine pharmacokinetics pharmacodynamics drug patient . - Determine antitumor effect drug patient . OUTLINE : This multicenter , dose-escalation study . Patients receive interleukin-7 ( IL-7 ) subcutaneously day 0 , 2 , 4 , 6 , 8 , 10 , 12 , 14 ( total 8 dos ) absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos IL-7 maximum tolerate dose ( MTD ) `` biologically active dose '' ( BAD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . The BAD define dose produce sustain 50 % increase CD3+ count patient 's baseline without unacceptable toxicity . Patients follow 1 , 3 , 6 month 1 year study completion . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 3.75-10 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy meeting follow criterion : No known curative therapy Failed standard therapy , define either lack response OR disease progression ( i.e. , least 25 % increase disease new disease ) Measurable evaluable disease No hematopoietic malignancy No primary carcinoma lung PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 80100 % Life expectancy At least 3 month Hematopoietic Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 No proliferative hematologic disease Hepatic AST ALT less 3 time upper limit normal ( ULN ) PT/PTT great 1.5 time ULN No document hepatitis B infection No document hepatitis C infection Renal Creatinine clearance great 60 mL/min Cardiovascular Ejection fraction great 45 % MUGA Hypertension ( rest blood pressure great 140/90 mm Hg ) must control standard antihypertensive therapy Pulmonary No severe asthma DLCO/VA great 50 % predict FEV_1 great 50 % predict Immunologic No autoimmune disease Peripheral CD3+ cell count great 300/mm^3 stable 4 successive determination HIV negative Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No medical psychiatric condition would preclude study compliance No cognitive impairment likelihood develop cognitive impairment study participation No need palliative therapy No splenomegaly PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior immunotherapy cytokine , antitumor vaccine , monoclonal antibody therapy prior initiation peripheral CD3 count determination No prior allogeneic hematopoietic stem cell transplantation No concurrent immunotherapy No concurrent biologic agent ( e.g. , growth factor monoclonal antibody ) Chemotherapy No concurrent chemotherapy Endocrine therapy No prior systemic corticosteroid therapy 72 hour within 2 week prior initiation peripheral CD3 cell count determination No concurrent chronic steroid therapy Radiotherapy Not specify Surgery No prior solid organ transplantation No prior splenectomy Other More 4 week since prior cytotoxic therapy prior initiation peripheral CD3 cell count determination No concurrent cytotoxic therapy No concurrent immunosuppressive therapy No concurrent medication treatment hypertension No concurrent chronic asthma medication No concurrent chronic anticoagulant ( e.g. , highdose warfarin , heparin , aspirin ) Lowdose oral warfarin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>